Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8

SAN DIEGO, July 31 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc.
(Nasdaq: HALO), a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix, today announced that it will
release financial results for the three and six months ended June 30, 2008
before market open on Friday, August 8, 2008.
Jonathan Lim, MD, President and Chief Executive Officer, Gregory Frost,
PhD, Vice President and Chief Scientific Officer, Robert Little, Vice
President and Chief Commercial Officer, David Ramsay, Vice President and Chief
Financial Officer, and Robert Uhl, Senior Director, Investor Relations, will
host an investment community conference call beginning at 8:00 a.m. PT (11:00
a.m. ET) on Friday, August 8, 2008, to provide a pipeline update.
Individuals interested in participating in the conference call may do so
by dialing 888-256-9044 for domestic callers or 706-643-5585 for international
callers. Those interested in listening to the conference call live via the
Internet may do so by visiting the Investor Relations section of the Company's
web site at http://www.halozyme.com. A replay will be available on Halozyme's
web site for 30 days. A telephone replay will be available for 48 hours by
dialing 800-642-1687 from the U.S., or 706-645-9291 for international callers,
and entering reservation code 57745069.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing
products targeting the extracellular matrix for the drug delivery, metabolism,
oncology and dermatology markets. The company's portfolio of products and
product candidates is based on intellectual property covering the family of
human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology
is a novel drug delivery platform designed to increase the absorption and
dispersion of biologics. Its key partnerships are with Roche to apply Enhanze
Technology to Roche's biological therapeutic compounds for up to 13 targets
and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic
compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA
approval for two products: Cumulase(R), for use in in-vitro fertilization, and
HYLENEX, for use as an adjuvant to increase the absorption and dispersion of
other injected drugs and fluids. HYLENEX is partnered with Baxter
International Inc. The Company also has a number of different enzymes in its
portfolio that are targeting significant areas of unmet need.
Halozyme Contact
Robert H. Uhl
Senior Director, Investor Relations
(858) 704-8264
ruhl@halozyme.com

SOURCE Halozyme Therapeutics, Inc.

Robert H. Uhl, Senior Director, Investor Relations of Halozyme Therapeutics,
Inc., +1-858-704-8264, ruhl@halozyme.com